A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02760485 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma

Interventions

DRUG: itacitinib
DRUG: ibrutinib

Sponsor

Incyte Corporation